According to Zacks, “Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. “
Other equities analysts have also recently issued reports about the company. ValuEngine cut Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. Stifel Nicolaus set a $7.00 price target on Endologix and gave the stock a hold rating in a report on Monday, April 1st. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $25.75.
Endologix (NASDAQ:ELGX) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported ($1.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.56) by $0.44. The firm had revenue of $35.61 million for the quarter, compared to analysts’ expectations of $34.18 million. Endologix had a negative return on equity of 173.52% and a negative net margin of 54.72%. Sell-side analysts predict that Endologix will post -3.65 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the business. Citigroup Inc. boosted its holdings in shares of Endologix by 279.2% during the 4th quarter. Citigroup Inc. now owns 51,448 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 37,882 shares in the last quarter. Macquarie Group Ltd. bought a new position in shares of Endologix in the 4th quarter worth $46,000. Jane Street Group LLC lifted its holdings in shares of Endologix by 54.6% in the 4th quarter. Jane Street Group LLC now owns 93,572 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 33,044 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Endologix by 408.0% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 99,731 shares of the medical instruments supplier’s stock worth $71,000 after purchasing an additional 80,100 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Endologix by 40.2% in the 4th quarter. Rhumbline Advisers now owns 106,979 shares of the medical instruments supplier’s stock worth $77,000 after purchasing an additional 30,701 shares in the last quarter. Hedge funds and other institutional investors own 47.07% of the company’s stock.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Further Reading: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.